Cimzia (certolizumab pegol) / Astellas, UCB 
Welcome,         Profile    Billing    Logout  
 50 Diseases   29 Trials   29 Trials   3299 News 


«12...2627282930313233343536...3839»
  • ||||||||||  Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_2184;    
    Before CZP treatment and besides oral corticosteroids, patients had received methotrexate (n=4), azathioprine (n=5), adalimumab (n=5), infliximab (n=2), golimumab (n=2), etanercept (n=2), sulfasalazine (n=1) and cyclosporine A (n=1). CZP seems to be effective and safe in patients with uveitis during pregnancy.
  • ||||||||||  Orencia (abatacept) / BMS, Enbrel (etanercept) / Takeda, Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_1459;    
    Discontinuations of DMARDs in clinical practice due to inefficacy are frequent (13.5%) with an IR of 4%. We have found differences in discontinuation rates among DMARD with Certolizumab, Abatacept, Etanercept, and Gold being the drugs with the highest risk.
  • ||||||||||  mTORC1-phosphorylated CXCR3+memory B Cells and Their Potential as a New Mode of Action of TNF Inhibitors in RA (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_1440;    
    We examined the change of percentage of CXCR3+CD27+CD19+ cells and the level of p-mTORC1 before and at 1 year after treatment with biologics (37 patients, TNF inhibitors (n=19: adalimumab:11, certolizumab:7, etanercept:1), abatacept (n=16), tocilizumab (n=2))...Combined stimulation of BCR, CD40L and IFN-γ induced CXCR3 expression on B cells, which were abrogated by mTORC1 inhibitors, Rapamycin... Taken together, activation of mTORC1 is involved in the accumulation of CXCR3-positive memory B cells in RA synovium and TNF inhibitors possibly target at this in patients with RA.
  • ||||||||||  Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_1375;    
    The subjects were 55 RA patients who filled RA criteria 2010, were treated with adalimumab, certolizumab pegol or golimumab, had serum RF titer ≥45 IU/ml at entry (at starting anti-TNF therapy, month 0), and were followed up until month 12. Continuous decrease in serum RF titer was associated with less progression in mTTS, especially in bone erosion score, of RA patients treated with TNF inhibitors.
  • ||||||||||  Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In Vitro (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_1175;    
    For each of the conditions tested in vitro, many resembling features associated with RA, the pre-formed complexes of ADA:TNF and CZP:TNF were significantly more effective in preventing the TNF-induced effects (decrease of surface TNF-RI and alpha-2,6 Sia; increase in NF-kB activation, ICAM-1 surface levels and apoptosis) on human monocytes than those complexes of TNF with ETN, IFX or GOL. Additional in vitro and in vivo studies need to be done to further elucidate these mechanistic differences.
  • ||||||||||  Clinical, Review, Journal, Monotherapy:  Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. (Pubmed Central) -  Oct 2, 2019   
    Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with methotrexate in the treatment of rheumatoid arthritis (RA), up to one-third of patients with RA are treated with monotherapy...Forty-four monotherapy studies of abatacept, adalimumab, baricitinib, certolizumab pegol, etanercept, sarilumab, sirukumab, tocilizumab, and tofacitinib reported in 71 publications were identified...There is, however, a need for longer-term head-to-head trials to establish positioning of these interventions in the treatment algorithm for RA. Pfizer.Plain Language Summary: Plain language summary available on the journal website.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Clinical, Review, Journal:  Certolizumab pegol for induction of remission in Crohn's disease. (Pubmed Central) -  Sep 27, 2019   
    It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small decrease or doubling of events. Future studies are needed to evaluate the long-term efficacy and safety of CZP in CD patients.
  • ||||||||||  Review, Journal:  Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. (Pubmed Central) -  Sep 26, 2019   
    The clinical-effectiveness evidence in the CS for BARI was based predominantly on three randomised controlled trials comparing the efficacy of BARI against adalimumab or placebo, as well as one long-term extension study...The company submitted a de novo discrete event simulation model that analysed the incremental cost-effectiveness of BARI versus its comparators for the treatment of RA from the perspective of the National Health Service (NHS) in four different populations: (1) cDMARD-IR patients with moderate RA, defined as a 28-Joint Disease Activity Score (DAS28) > 3.2 and no more than 5.1; (2) cDMARD-IR patients with severe RA (defined as a DAS28 > 5.1); (3) TNFi-IR patients with severe RA for whom rituximab (RTX) was eligible; and (4) TNFi-IR patients with severe RA for whom RTX in combination with methotrexate (MTX) is contraindicated or not tolerated...In the cDMARD-IR population with severe RA, BARI in combination with MTX dominated all comparators except for certolizumab pegol (CTZ) in combination with MTX, with the ICER of CTZ in combination with MTX compared with BARI in combination with MTX estimated to be £18,400 per QALY gained...In the TNFi-IR population with severe RA for whom RTX in combination with MTX is contraindicated or not tolerated, BARI in combination with MTX dominated golimumab in combination with MTX and was less effective and less expensive than the remaining comparators...The programming error that affected the PSA of the severe cDMARD-IR population had only a minimal impact on the results, while the error affecting the severe TNFi-IR RTX-ineligible population resulted in markedly higher costs and QALYs gained for the affected comparators but did not substantially modify the conclusions of the analysis. The NICE Appraisal Committee concluded that BARI in combination with MTX or as monotherapy is a cost-effective use of NHS resources in patients with severe RA, except in TNFi-IR patients who are RTX-eligible.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion, Trial completion date, Trial primary completion date:  PreCePRA: Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain (clinicaltrials.gov) -  Sep 26, 2019   
    P3,  N=156, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Jun 2021 --> Jun 2019 | Trial primary completion date: Dec 2020 --> Jun 2019
  • ||||||||||  Clinical, Review, Journal:  Maneuvering Clinical Pathways for Crohn's Disease. (Pubmed Central) -  Sep 16, 2019   
    Patient with inadequate response should have their trough level checked and therapy optimized. Therapeutic prophylaxis for post-operative recurrence should be based on patient's risk factors for recurrence.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Review, Journal:  In-label treatment of inflammatory joint diseases (Pubmed Central) -  Sep 11, 2019   
    A further example is that modifying the dose when the treatment goal is reached is only intended for some of the drugs in the course of the disease. Clinical trials which address such questions could help to modify or add to the label, as for example has now been successfully achieved for the treatment with certolizumab in pregnancy.
  • ||||||||||  Inflectra (infliximab biosimilar IV) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Journal:  Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages. (Pubmed Central) -  Sep 11, 2019   
    By contrast, we show that blockade of sTNFα by Cimzia does not affect T-cell proliferation and infection rates...Taken together, we provide an in vitro model of human leishmaniasis that allows direct comparison of different anti-TNFα agents. Our results enhance the understanding of the efficacy and adverse effects of TNFα blockers and they contribute to evaluate anti-TNFα therapy for patients living in countries with a high prevalence of leishmaniasis.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion:  Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) -  Sep 10, 2019   
    P3,  N=110, Completed, 
    Collaboration between surgeons and gastroenterologists appears to be very important to improve the rate of fistula closure. Active, not recruiting --> Completed
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Journal:  Oculomotor Nerve Demyelination Secondary to Certolizumab Pegol. (Pubmed Central) -  Aug 30, 2019   
    Further studies are still needed to evaluate the pathophysiology of NAFLD development and disease progression among IBD populations. No abstract available
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Journal:  Certolizumab Pegol-Induced Heart Failure. (Pubmed Central) -  Aug 23, 2019   
    Recruiting --> Completed | N=20 --> 41 | Trial completion date: Sep 2015 --> Aug 2019 | Trial primary completion date: Sep 2015 --> Mar 2019 No abstract available
  • ||||||||||  Retrospective data, Journal:  Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients. (Pubmed Central) -  Aug 21, 2019   
    All biological DMARDs used in combination with methotrexate, except for etanercept, anakinra, certolizumab and tocilizumab without methotrexate, were displayed ETA on using ACR50 at week 24 in patients naïve to biological DMARDs. Etanercept displayed a greater difference in responses, although the high uncertainty of the comparative results prevented the confirmation of the increased efficacy of this drug.
  • ||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
    Trial completion date, Trial primary completion date:  Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) -  Aug 20, 2019   
    P3,  N=163, Active, not recruiting, 
    Etanercept displayed a greater difference in responses, although the high uncertainty of the comparative results prevented the confirmation of the increased efficacy of this drug. Trial completion date: Jan 2021 --> Oct 2021 | Trial primary completion date: Dec 2020 --> Jul 2021